BPC-157 is one of the most talked-about peptides in regenerative and sports medicine circles, and also one of the most misunderstood. Most of what's written about it online is marketing copy dressed up as science. This isn't that. Below is what the actual peer-reviewed literature shows — what's been demonstrated in humans, what's still confined to animal and cell models, and where the honest gaps are.

What BPC-157 Is

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a protective protein naturally found in human gastric juice. Researchers, primarily a group based in Zagreb, Croatia, have been studying it since the 1990s, largely under the developmental name PL 14736. Mechanistically, its best-documented effects center on two processes: angiogenesis (the formation of new blood vessels, which is central to how damaged tissue gets the blood supply it needs to repair) and cytoprotection, a broader stabilizing effect on cell membranes and the gut lining that was first studied in the context of ulcers.

Tendon, Ligament, and Muscle Repair

This is where BPC-157 has generated the most interest from athletes and clinicians, and it's also where the evidence base is almost entirely preclinical — meaning animal and cell-culture studies, not human trials.

In isolated tendon fibroblast studies, BPC-157 was shown to promote cell migration, survival under stress, and outgrowth from tendon explants, an effect researchers linked to activation of the FAK-paxillin signaling pathway (Journal of Orthopaedic Research, 2011) [PubMed]. A related in-vitro study found BPC-157 upregulates growth hormone receptor expression in tendon fibroblasts, which in turn amplified the cell-proliferation effect of growth hormone itself (Molecules, 2014) [PMC — full text].

In rat models, BPC-157 accelerated healing of transected Achilles tendons, ligament tears, and disrupted myotendinous junctions, with treated animals showing better collagen organization, restored vascular density at the injury site, and a full return of function where untreated controls did not recover (Biomedicines, 2021) [PMC — full text]. Earlier rat work specifically on ligament healing showed similar acceleration of the repair timeline (Cerovecki et al., Journal of Orthopaedic Research, 2010).

A 2025 systematic review in the American Journal of Sports Medicine pulled this body of work together, screening the literature from database inception through mid-2024. The reviewers' conclusion is worth stating plainly: preclinical data consistently supports BPC-157's role in healing fractures, tendon and ligament tears, and muscle injury, but the human clinical evidence remains sparse, and BPC-157 is not FDA-approved and is a banned substance in professional sports [PubMed].

Gastrointestinal Healing — Where the Human Data Actually Lives

BPC-157's strongest human evidence comes from its original research application: inflammatory bowel disease. Before it was ever discussed for tendons, it was developed under the name PL 14736 as a potential ulcerative colitis therapy.

A first-in-human Phase I trial found that rectal administration of PL 14736 in healthy male volunteers was safe and well tolerated, with favorable pharmacokinetics that supported moving into patient trials (Veljaca et al., published in Gut, 2003). That led to a multicenter, randomized, double-blind, placebo-controlled Phase II trial testing PL 14736 enemas in patients with mild-to-moderate ulcerative colitis, presented by Ruenzi and the Ulcerative Colitis Study Group at the American Gastroenterological Association's Gastroenterology meeting in 2005. This is the single most substantial human clinical dataset that exists for BPC-157 to date — and it's worth noting the full trial results were never published as a standalone peer-reviewed paper, only referenced across the subsequent literature, which limits independent verification of the findings.

On the mechanistic side, animal research helps explain why: BPC-157 has been shown to protect intestinal permeability and reduce cytotoxic damage caused by NSAIDs, essentially reinforcing the gut lining under chemical stress (Current Pharmaceutical Design, 2020). Rat models of surgically created bowel fistulas and intestinal anastomosis (the reconnection of cut bowel) also showed accelerated, more complete healing with BPC-157 treatment, both when delivered systemically and directly to the site (Journal of Pharmacological Sciences, 2008; Journal of Surgical Research, 2007) [PubMed].

Inflammation and Vascular Effects

Underlying both the musculoskeletal and GI findings is BPC-157's angiogenic activity. In a rat model comparing muscle and tendon healing, researchers used a sponge implantation assay to directly measure new blood vessel formation and found BPC-157 modulated angiogenesis more effectively than standard reference compounds (Brcic et al., Journal of Physiology and Pharmacology, 2009). This vascular effect is the mechanistic thread connecting BPC-157's use across very different tissue types — tendon, gut lining, and skin all depend on adequate blood supply to repair themselves, and it's this pathway researchers point to most consistently across the animal literature.

Safety: What Human Data Exists

Human safety data on BPC-157 is real but still limited in scope. Beyond the early 2000s IBD trials, the most direct modern safety data comes from a small 2025 pilot study published in Alternative Therapies in Health and Medicine, in which two healthy adults received intravenous BPC-157 infusions up to 20 mg. Researchers tracked cardiac, hepatic, renal, and thyroid biomarkers along with vital signs before and after infusion and found no measurable adverse effects, with plasma levels returning to baseline within 24 hours [PubMed]. It's an honest, IRB-approved study — and also, by the authors' own acknowledgment, a two-person pilot with no control group, which is not sufficient on its own to establish safety at scale. That's the state of BPC-157 human research overall: promising signals, a real but small foundation, and a clear need for larger controlled trials that, so far, haven't materialized.

A Note on Regulatory Status

BPC-157 is not an FDA-approved drug for any condition. In 2023, the FDA placed it on Category 2 of its bulk drug substances list for compounding pharmacies, citing insufficient safety data; in April 2026, it was removed from that category after the original nominating parties withdrew their submission — but it has not been added to the FDA's approved Category 1 compounding list either. In practical terms, it currently sits in regulatory limbo: no longer explicitly restricted, but not formally cleared. Any BPC-157 program should only be pursued under the guidance of a licensed physician who can walk you through current regulatory status, sourcing, and whether it's appropriate for your specific case.

The Bottom Line

BPC-157's mechanism of action — driving angiogenesis and supporting tissue-level cytoprotection — is well characterized at the cellular and animal level, and its original human trials in ulcerative colitis, along with newer safety pilot data, are genuinely encouraging. What it isn't yet is a peptide with large, controlled human trials proving efficacy for tendon or ligament injury, which is the application generating the most consumer interest. Anyone considering it deserves that distinction clearly drawn, not blurred.

This article is for educational purposes only and does not constitute medical advice. BPC-157 is not FDA-approved for the treatment, diagnosis, prevention, or cure of any disease. Individuals considering peptide therapy should consult a licensed physician and conduct their own research before proceeding.